ERBB2 and neoplasm: Here, we describe the frequent occurrence of HER2 mutations, which emerge in patients receiving endocrine-based therapy for HR+ MBC, and utilize patient-derived ex vivo circulating tumor cell (CTC) cultures to demonstrate that such mutations are functional drivers susceptible to novel targeted inhibition.